Compare IRTC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | ACAD |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | 2016 | 2000 |
| Metric | IRTC | ACAD |
|---|---|---|
| Price | $117.66 | $22.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 22 |
| Target Price | ★ $197.92 | $30.55 |
| AVG Volume (30 Days) | 456.6K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.71 | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $747,138,000.00 | $726,437,000.00 |
| Revenue This Year | $19.60 | $18.80 |
| Revenue Next Year | $15.94 | $11.70 |
| P/E Ratio | ★ N/A | $1,116.75 |
| Revenue Growth | 26.24 | ★ 40.45 |
| 52 Week Low | $112.31 | $19.69 |
| 52 Week High | $210.01 | $28.35 |
| Indicator | IRTC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 48.49 |
| Support Level | $112.65 | $21.04 |
| Resistance Level | $127.50 | $22.03 |
| Average True Range (ATR) | 6.63 | 0.75 |
| MACD | -0.26 | 0.00 |
| Stochastic Oscillator | 20.84 | 33.92 |
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.